p16蛋白及PCNA在肾癌中的表达及意义

Expression of p16 protein and PCNA in renal cell carcinoma and their implications

目的探讨肾癌中p16蛋白与PCNA的表达与肾癌组织学类型、临床分期、病理分级及预后的关系。方法采用免疫组织化学SP法检测41例肾癌及18例癌旁正常肾组织中p16蛋白及PC－NA的表达。结果p16蛋白在肾癌及癌旁正常肾组织中的阳性表达率间具有显著性差异（P＜0.05），p16蛋白表达在肾透明细胞癌及颗粒细胞癌间无显著性差异，随肾癌分级、分期升高而明显降低，p16阳性表达组术后5年生存率明显高于阴性表达组；肾癌及癌旁肾组织中PCNA的阳性表达率增高，与预后有关，与肾癌的组织类型及分期无关。结论p16基因及蛋白的检测可作为肾癌的辅助诊断及预后判断的参考指标；PCNA可作为肿瘤恶性程度的判断及预后的参考指标。

Objective To study the expression of p16 protein and PCNA in renal cell carcinoma (RCC) and its relation to the RCC histological types, clinical stages, pathological grades, and prognosis. Method p16 and PCNA expression was immunohistochemically detected in 41 RCC cases and 18 cases of normal renal tissues adjacent to neoplastic lesions. Result The positive rate of p16 was higher in nonneoplastic tissue than in tumor tissue (P < 0. 05 ), and correlated with the stages, grades, and prognosis of the patients, but without significant difference between clear RCC and granular cell carcinoma. The positive rate of PCNA in tumor tissue and nonneoplastic tissue was related to the pathological grades and the prognosis of the patients. Conclusion p16 could he used as a predictor for diagnosis and prognosis of RCC, and PCNA as a marker in the evaluation of the malignancy and prognosis of RCC.